Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2741586 | 0.87 | TAAR1 (0.59) | HRH3TAAR1CYP2D6HRH4 | |
| SCHEMBL2626848 | 0.85 | HRH3 (0.57) | HRH3TAAR1CYP2D6HRH4ADRA2A | |
| SCHEMBL631902 | 0.83 | CHRM2 (0.52) | TAAR1CYP2D6HRH4 | |
| SCHEMBL2626850 | 0.81 | HRH3 (0.63) | HRH3TAAR1CYP2D6HRH4 | |
| SCHEMBL27986334 | 0.81 | HRH3 (0.62) | HRH3TAAR1HRH4 | |
| SCHEMBL2626846 | 0.79 | HRH3 (0.53) | HRH3TAAR1CYP2D6HRH4 | |
| SCHEMBL2626851 | 0.78 | HRH3 (0.52) | HRH3TAAR1CYP2D6HRH4ADRA2A | |
| SCHEMBL23528205 | 0.76 | CHRM2 (0.50) | TAAR1 | |
| SCHEMBL2626810 | 0.76 | HRH3 (0.65) | HRH3TAAR1CYP2D6HRH4ADRA2A | |
| SCHEMBL11228151 | 0.76 | HRH3 (0.65) | HRH3TAAR1CYP2D6HRH4ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158668-B2 | Methods for treating CNS disorders with 4-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158668-B2 | Methods for treating CNS disorders with 4-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1981880-B1 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085556-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | CRY1, GPR119, MTNR1A | HRH3 213/4885TAAR1 79/4885CYP2D6 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.